Physician profile
Benjamin M Wu
NPI 1740382381
$2,467.03
in general payments reported to CMS, 2019-2025
23 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $164 · 2021: $207 · 2022: $409 · 2023: $92.71 · 2024: $294 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $285.81 | 2025 | Aurora Ev-Icd Mri Surescan, Omniasecure Mri Surescan, Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.35 | 2019-2025 | Jardiance |
| Abbott Laboratories | $226.90 | 2020-2025 | Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $186.05 | 2021-2025 | |
| Philips North America LLC | $150.00 | 2019 | |
| Novo Nordisk INC | $147.10 | 2021-2022 | |
| Biosense Webster, INC. | $146.86 | 2025 | Carto 3 |
| Biotronik INC. | $144.33 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $140.64 | 2022 | |
| Bardy Diagnostics, INC. | $140.25 | 2019-2020 | |
| Amgen INC. | $127.09 | 2021-2025 | Repatha, Repatha |
| Penumbra, INC. | $122.66 | 2024 | Penumbra System |
| E.R. Squibb & Sons, L.L.C. | $68.87 | 2024-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $57.52 | 2024-2025 | |
| Esperion Therapeutics, INC. | $50.61 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.61 | 2025 | |
| Astellas Pharma US INC | $44.02 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.07 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $25.12 | 2024 | Onpattro |
| Edwards Lifesciences Corporation | $17.21 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Octapharma USA, INC. | $17.03 | 2025 | Fibryga |
| Kiniksa Pharmaceuticals, Ltd. | $16.44 | 2022 | |
| Boston Scientific Corporation | $13.49 | 2025 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.